CORCEPT THERAPEUTICS INC
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
CORT$73.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME
(In thousands, except per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Product revenue, net | $164,903 | $157,214 |
| Operating expenses: | ||
| Cost of sales | 2,883 | 2,403 |
| Research and development | 66,265 | 60,735 |
| Selling, general and administrative | 145,356 | 90,660 |
| Total operating expenses | 214,504 | 153,798 |
| (Loss) Income from operations | (49,601) | 3,416 |
| Interest and other income | 4,886 | 6,202 |
| (Loss) Income before income taxes | (44,715) | 9,618 |
| Income tax benefit | 12,954 | 10,929 |
| Net (loss) income | $(31,761) | $20,547 |
| Net (loss) income attributable to common stockholders | (31,202) | 20,288 |
| Basic net (loss) income per common share | $(0.30) | $0.19 |
| Diluted net (loss) income per common share | $(0.30) | $0.17 |
| Weighted-average shares outstanding used in computing net (loss) income per common share | ||
| Basic | 104,435 | 104,106 |
| Diluted | 104,435 | 119,819 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.